加载中
NASDAQHealthcareMedical - Devices
最新数据
US$1.50
−US$0.16 · -9.64%
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
前收盘价
US$1.50
−US$0.16 · -9.64%
盘后
US$1.52
+US$0.02 · +1.33%
10月7日 19:57 ET
盘中时间采用ET。市场数据可能有所延迟。
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
日内区间
当前US$1.50
52周区间
当前US$1.50
盘中时间采用ET。市场数据可能有所延迟。
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
日内区间
当前US$1.50
52周区间
当前US$1.50
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 280.4万 USD | 160.8万 USD | 203.6万 USD | 419.9万 USD | 766.3万 USD |
| 销售、一般及管理费用 | 2490.2万 USD | 299.2万 USD | 407.9万 USD | 524.4万 USD | 476.9万 USD |
| 营业费用 | 1322.3万 USD | 450万 USD | 607万 USD | 1114万 USD | 1169万 USD |
| 利息支出 | 509.5万 USD | 442.4万 USD | 428.3万 USD | 627万 USD | 407.9万 USD |
| 折旧和摊销 | — | — | — | 72.4万 USD | 118万 USD |
| 营业利润 | −1322.3万 USD | −450万 USD | −607万 USD | −1114万 USD | −1169万 USD |
| 净利润 | −3582.3万 USD | −923万 USD | −1028.1万 USD | −2021.7万 USD | −1031万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
